News Medical on MSN4d
Scientists analyze virus protein structure to advance RSV vaccines
In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) ...
cidrap.umn2d
US respiratory virus activity remains low ahead of holiday season
Respiratory virus activity remained low in the United States last week, with COVID levels continuing to decline, but ...
Macau Business4h
ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610,...
(“ArkBio”) announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a ...
Nursing in Practice3d
RSV jab rollout sees more than one million vaccinated
More than a million people have received a vaccination against respiratory syncytial virus (RSV) following its rollout this ...
earth4d
How the COVID-19 virus travels deep inside our lungs
New COVID-19 research uncovers viral behavior insights, driving innovative treatments with Northwestern Medicine's support.
Vaccination rates for flu and Covid are low this season, CDC says
Vaccination rates for Covid and the flu are low for adults in the U.S. so far this season, according to a new CDC report.
Medscape9d
Nirsevimab Resistance Mutations Rare in RSV, Study Shows
Widespread distribution of nirsevimab to infants with respiratory syncytial virus infection raised concerns about potential ...
Business Insider3d
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
targeting respiratory syncytial virus (RSV) and malaria utilizing the company’s proprietary C1 protein production platform to provide globally accessible treatment options for underserved populations.